Pharmacogenetics of methylphenidate response in attention deficit/hyperactivity disorder: Association with the dopamine transporter gene (<i>SLC6A3</i>)
Diane Purper‐Ouakil(Inserm), Philip Gorwood(Inserm), M. Wohl(Centre National de la Recherche Scientifique), Silvia Orejarena(Assistance Publique – Hôpitaux de Paris), Claudette Boni(Inserm), M. van Asch(Assistance Publique – Hôpitaux de Paris), Marie‐Christine Mouren, Samuele Cortese(King's College London)
American Journal of Medical Genetics Part B Neuropsychiatric Genetics
June 18, 2008
Cited by 54
Related Papers
How mental health care should change as a consequence of the COVID-19 pandemic
|The Lancet Psychiatry|2020|1.9k
The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder
|Neuroscience & Biobehavioral Reviews|2021|1.4k
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy
|Nature Reviews Drug Discovery|2012|1.3k
The consequences of the COVID-19 pandemic on mental health and implications for clinical practice
|European Psychiatry|2020|1.2k